Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.

ABSTRACT:

SUBMITTER: Moreau P 

PROVIDER: S-EPMC12375812 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature